Siddharth S Madapoosi,Charmion Cruickshank-Quinn,Kristopher Opron,John R Erb-Downward,Lesa A Begley,Gen Li,Igor Barjaktarevic,R Graham Barr,Alejandro P Comellas,David J Couper,Christopher B Cooper,Christine M Freeman,MeiLan K Han,Robert J Kaner,Wassim Labaki,Fernando J Martinez,Victor E Ortega,Stephen P Peters,Robert Paine,Prescott Woodruff,Jeffrey L Curtis,Gary B Huffnagle,Kathleen A Stringer,Russell P Bowler,Charles R Esther Jr,Nichole Reisdorph,Yvonne J Huang,SPIROMICS Research Group,Neil E Alexis,Wayne H Anderson,Mehrdad Arjomandi,Lori A Bateman,Surya P Bhatt,Eugene R Bleecker,Richard C Boucher,Stephanie A Christenson,Gerard J Criner,Ronald G Crystal,Claire M Doerschuk,Mark T Dransfield,Brad Drummond,Craig Galban,Nadia N Hansel,Annette T Hastie,Eric A Hoffman,Richard E Kanner,Eric C Kleerup,Jerry A Krishnan,Lisa M LaVange,Stephen C Lazarus,Deborah A Meyers,Wendy C Moore,John D Newell Jr,Laura Paulin,Cheryl Pirozzi,Nirupama Putcha,Elizabeth C Oelsner,Wanda K O'Neal,Sanjeev Raman,Stephen I Rennard,Donald P Tashkin,J Michael Wells,Robert A Wise

Abstract:Rationale: Chronic obstructive pulmonary disease (COPD) is variable in its development. Lung microbiota and metabolites collectively may impact COPD pathophysiology, but relationships to clinical outcomes in milder disease are unclear. Objectives: Identify components of the lung microbiome and metabolome collectively associated with clinical markers in milder stage COPD. Methods: We analyzed paired microbiome and metabolomic data previously characterized from bronchoalveolar lavage fluid in 137 participants in the SPIROMICS (Subpopulations and Intermediate Outcome Measures in COPD Study), or (GOLD [Global Initiative for Chronic Obstructive Lung Disease Stage 0-2). Datasets used included 1) bacterial 16S rRNA gene sequencing; 2) untargeted metabolomics of the hydrophobic fraction, largely comprising lipids; and 3) targeted metabolomics for a panel of hydrophilic compounds previously implicated in mucoinflammation. We applied an integrative approach to select features and model 14 individual clinical variables representative of known associations with COPD trajectory (lung function, symptoms, and exacerbations). Measurements and Main Results: The majority of clinical measures associated with the lung microbiome and metabolome collectively in overall models (classification accuracies, >50%, P < 0.05 vs. chance). Lower lung function, COPD diagnosis, and greater symptoms associated positively with Streptococcus, Neisseria, and Veillonella, together with compounds from several classes (glycosphingolipids, glycerophospholipids, polyamines and xanthine, an adenosine metabolite). In contrast, several Prevotella members, together with adenosine, 5'-methylthioadenosine, sialic acid, tyrosine, and glutathione, associated with better lung function, absence of COPD, or less symptoms. Significant correlations were observed between specific metabolites and bacteria (Padj < 0.05). Conclusions: Components of the lung microbiome and metabolome in combination relate to outcome measures in milder COPD, highlighting their potential collaborative roles in disease pathogenesis.

First Exploration of the Altered Microbial Gut–Lung Axis in the Pathogenesis of Human Refractory Chronic Cough

The Role of Microaspiration in the Pathogenesis of Gastroesophageal Reflux-related Chronic Cough

Mechanisms and Rationale for Targeted Therapies in Refractory and Unexplained Chronic Cough

Faecal microbial transfer and complex carbohydrates mediate protection against COPD

Fecal microbial transfer and complex carbohydrates mediate protection against COPD

Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease

Lung microbiome, gut–lung axis and chronic obstructive pulmonary disease

Gut–lung Microbiota Interactions in Chronic Obstructive Pulmonary Disease (COPD): Potential Mechanisms Driving Progression to COPD and Epidemiological Data

Lung and Gut Affair

COPD and Gut–Lung Axis: How Microbiota and Host Inflammasome Influence COPD and Related Therapeutics

Cough in chronic lung disease: a state of the art review

Impact of Lung Microbiota on COPD

Beneficial Bacteria in the Gut Microbiota May Lead to Improved Metabolic and Immunological Status in Chronic Obstructive Pulmonary Disease

The lung microbiome: clinical and therapeutic implications

Gut-Lung Microbiota in Chronic Pulmonary Diseases: Evolution, Pathogenesis, and Therapeutics

Future Directions in Chronic Cough

Lung Microbiota and Metabolites Collectively Associate with Clinical Outcomes in Milder Stage Chronic Obstructive Pulmonary Disease

Comprehensive analysis of the gut microbiota in patients with chronic obstructive pulmonary disease of varying severity-A prospective, observational study

WAO-ARIA consensus on chronic cough - Part II: Phenotypes and mechanisms of abnormal cough presentation - Updates in COVID-19

Gut microbiota dysbiosis contributes to the development of chronic obstructive pulmonary disease

Patient-reported experiences with refractory or unexplained chronic cough: a qualitative analysis